Treatment with the dipeptidyl peptidase-1 inhibitor brensocatib increases the antimicrobial peptide secretory leukocyte peptidase inhibitor (SLPI) in patients with bronchiectasis: results from the WILLOW trial

Bronchiectasis

Chair(s): Michael Loebinger, Pieter Goeminne

Session type: Oral presentation

Lidia Perea

EVENTS HOME

Previous presentation

Next presentation

Session content

Late Breaking Abstract - Bronchoalveolar lavage amylase level as a promising biomarker of aspiration: a multicenter cross-sectional clinical study

Lianjun Lin

Replay

Poster

Abstract

Slides

Neutrophil metabolomics in bronchiectasis: data from the EMBARC BRIDGE study

Amelia Shoemark

Replay

Poster

Abstract

Slides

Blood eosinophils, inhaled corticosteroids and exacerbations in bronchiectasis: Data from the EMBARC registry

Jennifer Pollock

Replay

Poster

Abstract

Slides

Validation of the Rose Criteria for COPD-Bronchiectasis Overlap: Data from the European Bronchiectasis Registry (EMBARC)

Letizia Traversi

Replay

Poster

Abstract

Slides

Lidia Perea

Replay

Poster

Abstract

Slides

Bronchiectasis and mortality in smokers with distinct spirometric phenotypes

Alejandro A Diaz

Replay

Abstract

Slides

qPCR and 16S rRNA marker-gene sequencing as endpoints for clinical trials of antimicrobials: iBEST study

Michael M Tunney

Replay

Poster

Abstract

Slides

Anxiety, depression and bronchiectasis outcomes: Data from the BronchUK study

Jennifer Pollock

Replay

Poster

Abstract

Slides

Genetic diversity of Pseudomonas aeruginosa virulence factors in bronchiectasis

Rebecca C Hull

Replay

Poster

Abstract

Slides

Bronchiectasis and cardiovascular risk: a systematic review and meta-analysis

Ivan Barone

Replay

Poster

Abstract

Slides

Discussion and Q&A

The ERS International Congress 2023, Milan

#{title}